Sepetaprost clinical trials
Also written ONO-9054.
How each study uses sepetaprost is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2012 (2)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2014 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2023 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 0
Santen Pharmaceutical Co., Ltd. (3) · Ono Pharma USA Inc (2) · Santen Inc. (1) · Ono Pharmaceutical Co. Ltd (1)
Studies
Open first, then newest update. How each study uses sepetaprost is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Long Term Study of STN1012600 in Subjects With Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT05503901Written as STN1012600 ophthalmic solution 0.002%
- Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males VolunteersCompletedPhase 1Santen Pharmaceutical Co., Ltd.NCT05905653Written as STN1012600 ophthalmic solution 0.002%
- A Comparative Confirmatory Study of STN1012600 in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 3Santen Pharmaceutical Co., Ltd.NCT05495061Written as STN1012600 ophthalmic solution 0.002%
- Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular HypertensionCompletedPhase 2Santen Inc.NCT04742283Written as DE-126 Ophthalmic Solution 0.002% QD
- A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)CompletedPhase 2Ono Pharmaceutical Co. LtdNCT02083289Written as ONO-9054
- Single and Multiple Dose Escalation and Two-sequence Crossover Study of ONO-9054 in Patients With Ocular Hypertension or Mild Open-angle GlaucomaCompletedPhase 1Ono Pharma USA IncNCT01670266Written as ONO-9054
- Single Dose Escalation Study of ONO-9054 in Healthy VolunteersCompletedPhase 1Ono Pharma USA IncNCT01508988Written as ONO-9054
Codes
What other systems call sepetaprost · ClinicalTrials.gg INT000451
- UNII (FDA) 79O7855J4GSEPETAPROSTConfirmed FDA, NLM, Wikidata
- Wikidata Q27266770sepetaprostConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152337SepetaprostOne source FDA
- DrugBank DB12043One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 79O7855J4G | SEPETAPROST | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27266770 | sepetaprost | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152337 | Sepetaprost | One source FDA |
| DrugBank | DB12043 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.